HAL Allergy Group news

As of 1 July 2021, the Supervisory Board of the HAL Allergy Group has appointed Alex Huybens as Chief Executive Officer (CEO) and Member of the Board of HAL Allergy Holding B.V., as well as CEO of HALIX B.V.

Alex Huybens, Master of Business Administration (MBA) and with a degree in Engineering, started his career at HAL Allergy in 2003. In the following years, he took responsibility in several positions in Production, Supply Chain Management, Technical Services, Biochemis

 HAL Allergy S.r.l. announced the start of its ‘Prima Linea’ initiative offering telephone counseling for the highly committed hospital staff, who are engaged in the daily fight with the coronavirus in the most affected regions of Italy.

All health and non-health workers, in the hospitals in Italy are working relentlessly with great courage to cope with the increasing number of CoVid-19 patients and its consequences. The commitment of every involved staff

We are very pleased to announce that the Supervisory Board has appointed Dr. Hans van Schijndel as Member of the Board of HAL Allergy Holding B.V. in the position of Chief Research & Development Officer (Chief R&D Officer) as of 1 February 2020.

With this appointment, the Board of Directors is now complete. Next to Dr. Hans van Schijndel, in charge of the R&D program, the Board consists of Florian Rösch being the Chief Commercial & Financial Officer a

HAL Allergy B.V. today announced the registration of SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml in Germany. These are the first marketing authorisations granted by the Paul Ehrlich Institute following the German Therapieallergene-Verordnung (TAV).

The TAV was initiated by the German Federal Ministry of Health on 14 November, 2008, and regulates the marketing authorisation requirements for frequent the